Innovative Change : PharmSource: Demand and Supply for Contract Manufacturing of Injectable Drugs Through 2023
ResearchMoz presents professional and in-depth study of "PharmSource: Demand and Supply for Contract Manufacturing of Injectable Drugs Through 2023".
Summary
This report is the 6th edition of our long-running analysis of the injectables CMO industry. It provides an expert quantitative analysis on the latest trends and plans for outsourcing commercially approved injectable products.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1654059
It combines the rich data resources of PharmSource and the GlobalData Pharmaceutical Intelligence Center with our 20 years experience in analyzing the injectables CMO industry to provide the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm.
Scope
- The report is based on the most recent data on industry capacity, the injectables pipeline and the behaviors of the key biopharmaceutical industry actors.
- The model and assumptions are fully explained so you can understand how the analysis was driven and how conclusions were reached.
Reasons to buy
This 70-page report gives important, expert insight you wont find in any other source. Over 25 tables and graphs throughout the report illustrate major points and trends. This report is required reading for -
- CMO executives who must have deep understanding of the injectables marketplace to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
View Complete TOC with tables & Figures @ https://www.researchmoz.us/pharmsource-demand-and-supply-for-contract-manufacturing-of-injectable-drugs-through-2023-report.html/toc
Table of Contents
Chapter 1: Executive Summary 1
Chapter 2: Objectives and Methodology 3
Methodology 3
Chapter 3: Recent Trends in Injectables NDA/BLA Approvals 5
Injectables approvals overview 5
NDA/BLA approvals of injectable products 6
Injectable NDA/BLA approvals by sponsor type 10
Processing and packaging characteristics 12
Contract manufacturing of injectable NDA/BLA approvals 15
European biosimilar approvals 18
Cytotoxic drug approvals 19
CMOs winning NDA/BLA approvals 20
What it means 21
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1654059
Chapter 4: Injectables Pipeline 24
Pipeline Overview 24
Biosimilars 27
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
Summary
This report is the 6th edition of our long-running analysis of the injectables CMO industry. It provides an expert quantitative analysis on the latest trends and plans for outsourcing commercially approved injectable products.
Get PDF for more Professional and Technical insights @ https://www.researchmoz.us/enquiry.php?type=S&repid=1654059
It combines the rich data resources of PharmSource and the GlobalData Pharmaceutical Intelligence Center with our 20 years experience in analyzing the injectables CMO industry to provide the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm.
Scope
- The report is based on the most recent data on industry capacity, the injectables pipeline and the behaviors of the key biopharmaceutical industry actors.
- The model and assumptions are fully explained so you can understand how the analysis was driven and how conclusions were reached.
Reasons to buy
This 70-page report gives important, expert insight you wont find in any other source. Over 25 tables and graphs throughout the report illustrate major points and trends. This report is required reading for -
- CMO executives who must have deep understanding of the injectables marketplace to make strategic planning and investment decisions.
- Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
View Complete TOC with tables & Figures @ https://www.researchmoz.us/pharmsource-demand-and-supply-for-contract-manufacturing-of-injectable-drugs-through-2023-report.html/toc
Table of Contents
Chapter 1: Executive Summary 1
Chapter 2: Objectives and Methodology 3
Methodology 3
Chapter 3: Recent Trends in Injectables NDA/BLA Approvals 5
Injectables approvals overview 5
NDA/BLA approvals of injectable products 6
Injectable NDA/BLA approvals by sponsor type 10
Processing and packaging characteristics 12
Contract manufacturing of injectable NDA/BLA approvals 15
European biosimilar approvals 18
Cytotoxic drug approvals 19
CMOs winning NDA/BLA approvals 20
What it means 21
Make An Enquiry @ https://www.researchmoz.us/enquiry.php?type=E&repid=1654059
Chapter 4: Injectables Pipeline 24
Pipeline Overview 24
Biosimilars 27
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
90 State Street, Albany NY, United States - 12207
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Follow us on LinkedIn @ http://bit.ly/1TBmnVG
Follow me on : https://marketinfo247.wordpress.com/
Comments
Post a Comment